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Purpose/Objective: High dose image guided radiotherapy (IGRT) using 
prostate fiducials is standard of care for low and intermediate risk 
patients. However, high risk patients also benefit from prophylactic 
intensity modulated radiotherapy (IMRT) to the lymph nodes. The 
prostate can move independently to the pelvic nodes, therefore the 
safety of combining fiducial IGRT and pelvic nodal IMRT in high risk 
patients is uncertain. We aim to ascertain the dosimetric impact of 
employing fiducial-based hybrid IG-IMRT on the lymph node planning 
target volume (PTV).  
Materials and Methods: Thirty consecutive IMRT prostate and pelvic 
lymph node dosimetric plans were retrospectively reviewed after 
recalculation with incremental 1mm isocentre movements in all 
directions up to 10mm. In our centre, all IGRT images and shifts are 
recorded creating a population based database. Combining this 
database and the dosimetric data we calculated the overall risk of 
failing to maintain the following lymph node PTV statistics with 
fiducial IG-IMRT:  
- PTV receiving > 99% of target dose (V99%) > 90%,  
- PTV receiving > 95% of target dose (V95%) > 95%  
- PTV receiving > 50% of target dose (V50%) > 100%. 
Results: Shifts in the left, right, and anterior directions do not have a 
significant impact on dose delivery with less than 0.25% risk of PTV 
coverage failure. Shifts posteriorly have the largest impact on dose 
but this still has less than 1% risk of failing PTV coverage.  
Conclusions: The risk of failing lymph node PTV coverage is very low 
with IG-IMRT and therefore we recommend adopting IG-IMRT in high 
risk prostate cancer patients receiving prophylactic lymph node 
irradiation. This will allow a reduction in CTV to PTV margins to the 
prostate volume leading to reduced toxicity and scope for dose 
escalation. 
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Purpose/Objective: Technological advanced in stereotactic body 
radiation therapy have allowed precise targeting and delivery of 
radiation to the prostate while sparing normal tissues. This is suitable 
device for performing hypofractionated stereotactic body 
radiotherapy. We report our experience using cyberknife to patients 
with localized prostate cancer.  
Materials and Methods: This study was based on a retrospective 
analysis of the 65 patients treated with CyberKnife radiotherapy for 
localized prostate cancer. Image-guided SBRT was delivered to all 
patients using the CyberKnife (Accuray Inc., Sunnyvale, CA) with 
motion tracking of internal fiducial seeds. Thirty-five patients 
identified as low and favorable intermediate risk group received 
irradiation at a dose of 36.25 Gy in 5 fractions of 7.25 Gy per fraction. 
Thirty-two unfavorable intermediate and high risk group patients 
received 45 Gy at whole pelvis by three dimensional radiation therapy 
or intensity modulated radiation therapy and received a boost by the 
CyberKnife at dose of 21 Gy in 3 fractions. The acute and late 
toxicities were recorded using the Radiation Therapy Oncology Group 
scale and the CTCAE, version 4.0. Prostate-specific antigen response 
was monitored. 
Results: All 65 patients finished planed radiation therapy without any 
severe complication. The median follow-up for patients was 36 
months (range 6 - 56 months). There were two biochemical failures in 
high risk patient who received whole pelvis radiation therapy and 
cyberknife boost. Acute Grade 1 and Grade 2 gastrointestinal (GI) 
toxicities were observed in 38.5% and 3.1% of the patients, 
respectively. There were no acute Grade 3 or 4 GI toxicities. Late 
Grade 3 GI toxicity, rectal bleeding, was noted in 2 patient in high risk 
group (3.1%) but bleeding was stopped with 3 times laser coagulation 
in one patients. Acute Grade 1 and Grade 2 genitourinary (GU) 
toxicities were seen in 43.1% and 21.5%of the patients, respectively. 
There was acute Grade 3 urinary frequency in one patients of high risk 
group.  
Conclusions: Our results showed favorable biochemical response and 
low toxicity for hypofractionated stereotactic body radiotherapy with 
CyberKnife for localized prostate cancer. However, more follow up 
with a larger cohort is required to confirm durable biochemical 
control rates and late toxicity profiles.  
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Purpose/Objective: To determine the optimal planning target volume 
(PTV) margins in image-guided radiotherapy (IGRT) for prostate 
cancer, intra-fraction prostate motion was examined. 
Materials and Methods: During 32 fractions of Cyberknife treatment, 
prostate motion as tracked by the stereoscopic X-ray images of the 
implanted fiducials was examined. The CyberKnife uses a stereoscopic 
X-ray system to obtain the position of the prostate target through the 
monitoring of implanted fiducial markers. If there is a significant 
deviation, the treatment is paused while the patient is repositioned 
by moving the couch. The deviations calculated from X-ray images 
acquired within the time interval between two consecutive couch 
motions constitute a data set. 
Results: The averages of intra-fractional motion of fiducial markers 
were 1.1 mm for cranio-caudal, 0.3 mm for left-right, and 1.2 mm for 
antero-posterior. The maximum of intra-fractional motion of fiducial 
markers were 7.9 mm for cranio-caudal, 2.1 mm for left-right, and 
11.5 mm for antero-posterior. Intra-fractional fiducial marker motion 
of 5.0 mm or greater was observed only in two fractions among 32 
fractions. In addition, incidence of intra-fractional fiducial marker 
motion of 3.0 mm or greater increased with time in cranio-caudal and 
antero-posterior. 
Conclusions: Although PTV margins of 10 mm or greater is necessary 
to completely cover the intra-fractional prostate motion, PTV margins 
of 5 mm were adequate to cover the cranio-caudal and antero-
posterior intra-fractional prostate motion in more than 90% of 
fractions. PTV margins of left-right seemed to be able to reduce to 3 
mm. Reduction of treatment time is needed to reduce the PTV 
margins in IGRT of prostate cancer. 
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Purpose/Objective: To investigate the spatial and temporal 
variability of the endorectal balloon (ERB) position in the setting of 
postoperative radiotherapy and to investigate the impact of ERB 
variability on the dose delivered to the rectal wall (Rwall). 
Materials and Methods: For 7 patients with biochemical recurrence 
after prostatectomy and referred for salvage radiotherapy of the 
prostate bed, a daily-inserted air-filled (50ml) ERB was applied and a 
VMAT planning technique was used. The prescription dose was 66Gy 
(2Gy/fraction). During treatment, weekly control CTs were acquired 
and translational matches to the reference CT by means of 
surrounding pelvic bones (symphysis etc.) were performed. Rectum, 
rectum balloon and rectal wall structures were contoured and the 
original treatment plan was calculated on the control CT. The relative 
volumes of Rwall exposed to doses ≥ 40Gy (V40), ≥ 60Gy(V60), ≥ 
65Gy(V65) were calculated. Additionally, the balloon shifts (changes in 
distance from the rectum balloon center to the isocenter) were 
measured. The dose volumes and balloon shifts were plotted against 
the time (number of days between the respective control CT and the 
planning CT). Significance tests were made for each patient for 
detecting systematic changes over treatment time. 
Results: The figure shows a graph of the balloon shifts for each 
patient over time. R2 statistics and p values were calculated to check 
if the observed trend that the balloon shifts away from the isocenter 
over time was significant. Significance was found only in one patient. 
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The relative difference of V40, V60 and V65 between the planned value 
and the mean value of control plans were ?V40=-1% ± 16%, ?V60=-11% ± 
13%, ?V65=-31% ± 33%. 
Conclusions: The results indicate that there are variations in balloon 
position, with a tendency towards increased distance to the isocenter 
over time compared to the planning CT. This induces V65 and V60 to 
decrease whereas V40 is rather robust to the balloon shift. We could 
show that the dose to the rectal wall during treatment was the same 
or lower compared to the planned dose.  
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Purpose/Objective: Cone beam computed tomography (CBCT) 
verification images are typically obtained pre-radiotherapy for step 
and shoot intensity modulated radiotherapy (IMRT). Volumetric 
modulated arc therapy (VMAT) allows IMRT to be delivered using 
single or multiple treatment arcs and CBCT images can be acquired 
efficiently during treatment as the gantry rotates (simultaneous CBCT, 
sCBCT). These images are subject to image degradation from 
megavoltage scatter. The objective of this study is to assess feasibility 
of reliable organ delineation, and to compare organ position, on 
sCBCT as compared to CBCT in patients treated for prostate cancer. 
Materials and Methods: Five patients had standard CBCT images and 
sCBCT images taken on fractions 2, 6, 11 and 16 of radical 
radiotherapy for prostate cancer. Each sCBCT image was corrected to 
account for MV scatter and improve image quality, yielding 3 datasets 
per fraction: pre-treatment CBCT, uncorrected sCBCT (usCBCT) and 
corrected sCBCT (csCBCT). Thus 12 images per patient were available 
for analysis. Prostate, rectum and bladder volumes were delineated 
using Pinnacle v9.0 by two observers. The conformity of comparative 
volumes between each pre-delivery CBCT and corresponding usCBCT 
and csCBCT was assessed using the Dice Similarity Coefficient (DSC: 1= 
unity, 0=no overlap of volumes). Mean centroid shift (geometric 
centre of mass) was calculated to assess gross volume movement. 
Results: Results are shown in table 1. 
 
 Conclusions: Mean DSC values indicate a promising degree of 
conformity between standard CBCT and sCBCT, albeit with relatively 
large variation in centroid position. This may represent true variation 
in organ position between acquisition of CBCT and sCBCT, however 
the data set is small and inter- and intra-observer variability in 
outlining, in addition to contouring uncertainties due to poorer image 
quality of sCBCT may explain the disparity. Correction of sCBCT 
images does not appear to enhance conformity over uncorrected 
images. Outlining target and organ at risk volumes on sCBCT is 
feasible, and thus sCBCT acquired have great potential for clinical 
practice. Using current techniques, the dose to the CTV and organs at 
risk is calculated using the radiotherapy planning CT. This represents 
a single point in time and dose predictions will not be completely 
accurate due to patient and organ motion during the course of 
treatment. sCBCT allows the position of structures to be identified 
during treatment delivery thereby removing this temporal disconnect 
and positional uncertainty. Ultimately intra-fraction imaging may 
allow the dose received by structures to be calculated more 
accurately and correlated with patient outcome and toxicity, in 
addition to increasing centre throughput and efficiency. This 
technique warrants further evaluation.  
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Purpose/Objective: Hyperthermia (HT) is part of an ongoing bladder 
preservation national phase II trial using combined chemoradiotherapy 
following transurethral resection in T2-4NxM0 bladder tumours in a 
national trial. According to the protocol intravesical temperatures 
between 41.5°C to 42.5°C had to be reached for 60 minutes at the 
weekly HT sessions delivered by the deep HT unit,BSD-2000. The aim 
of this study was to evaluate quality of heating, monitor specific 
thermal parameters during the HT sessions and explore the extent of 
their variability during multiple sessions. 
Materials and Methods: Eight patients have been recruited in the 
protocol so far. A total of 43 HT sessions were delivered. Real time 
bladder temperatures were monitored using intravesical thermometry 
during 60 minutes of HT delivery. The thermal parameters evaluated 
were - minimum, maximum and average temperatures (Tmin, Tmax and 
Tav)respectively, temperature received by 20%, 50% and 90% of the 
target (T20,T50and T90) respectively, cumulative equivalent minutes of 
T90above 43°C (CEM43T90) and thermal dose (TD). 
Results: Of the 8 patients, 7 achieved a clinical complete response at 
completion of treatment. A total of 327 temperature data points were 
available for the analysis. Details of the measured values are 
summarized in the Table. Significant variability in the various thermal 
parameters was not observed, both within the individual patients and 
across the 8 patients. CEM43T90 was found to have aquadratic relation 
with Tmin, obtained by the expression, CET43T90= 5805.61 – 291.7(Tmin) 
+ 3.66(Tmin)2 (model r2=0.90,p<0.001) while TD could be derived from 
the expression, TD= -165.2 + 13.3(Tav) + 1.3(CET43T90) -9.3(T90), 
(model r2=0.89,p<0.001). 
  
Conclusions: The various thermal parameters evaluated have not 
shown significant variability during multiple HT sessions. This could be 
a consequence of effective phase and amplitude steering feasible with 
the Sigma Eye HT applicator during these HT sessions. Mathematical 
models for computation of the key parameters, namelyCEM43T90 and 
TD were derived, which in future could be used to evaluate their roles 
as potential predictors of thermotherapy. 
   
